We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
MannKind Corporation (MNKD)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.3000 |
| Open | 4.3000 |
| Bid | 4.1200 x 700 |
| Ask | 4.1700 x 700 |
| Day's Range | 4.1000 - 4.3300 |
| 52 Week Range | 3.1700 - 5.7500 |
| Volume | |
| Avg. Volume | 3,037,788 |
| Market Cap | 1.124B |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | May 07, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.08 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MNKD
Related Research
- MannKind CorporationDVAX: What does Argus have to say about DVAX?DYNAVAX TECHNOLOGIES CORP has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.RatingFair ValueEconomic Moat4 days agoArgus Research
GlobeNewswireMannKind Repays Certain Debt Obligations
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common stock and approximately $8.9 millionTotal debt reduced since December 31, 2023 is approximately $41.8 million DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled thera
Simply Wall St.MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returns
Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be vulnerable to their...
ZacksIovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
MannKind Announces CFO Transition
Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024, through December 31, 2024Christopher Prentiss appointed Chief Financial Officer, effective April 22, 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lu
Insider MonkeyJim Cramer Says You Should Avoid These 11 Stocks
In this article, we will take a detailed look at Jim Cramer Says You Should Avoid These 11 Stocks. For a quick overview of such stocks, read our article Jim Cramer Says You Should Avoid These 5 Stocks. Jim Cramer in his latest program took a jab at the Department of Justice and Washington authorities in general, calling regulators […]
- GlobeNewswire
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
Post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumpsSubjects utilizing inhaled insulin experienced a 22% decrease in mean glucose excursions in the first two hours compared to the standard of care17-week primary endpoint results will be presented during a 90-minute symposium at the American Diabetes Association’s Scientific Sessions in June DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 11, 202
- GlobeNewswire
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that new clinical data from the I
- GlobeNewswire
MannKind Corporation Announces Participation at Upcoming Conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences. Leerink Partners Global Biopharma Conference 2024 – Investor Meetings, Monday, March 11, 2024 Oppenheimer 34th Annual Healthcare MedTech & Services Confere
- Simply Wall St.
Analysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) Forecasts
Celebrations may be in order for MannKind Corporation ( NASDAQ:MNKD ) shareholders, with the analysts delivering a...
Simply Wall St.MannKind Full Year 2023 Earnings: Beats Expectations
MannKind ( NASDAQ:MNKD ) Full Year 2023 Results Key Financial Results Revenue: US$199.0m (up 99% from FY 2022). Net...
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| GERN Geron Corporation | |||
| CLDX Celldex Therapeutics, Inc. | |||
| ACAD ACADIA Pharmaceuticals Inc. | |||
| AMRN Amarin Corporation plc | |||
| BCRX BioCryst Pharmaceuticals, Inc. |
Similar to MNKD
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| UTHR United Therapeutics Corporation | |||
| LQDA Liquidia Corporation | |||
| IOVA Iovance Biotherapeutics, Inc. | |||
| PBYI Puma Biotechnology, Inc. | |||
| GERN Geron Corporation |
Analyst Price Targets (6)
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/15/2024 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 2/28/2024 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/4/2024 | |
| Initiated | Wedbush: to Outperform | 10/10/2023 | |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/14/2023 | |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 8/8/2023 |
Company Profile
1 Casper Street
Danbury, CT 06810
United States
818 661 5000
https://www.mannkindcorp.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 411
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
